UCSF scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies.
Using a mouse model, researchers showed that a drug that temporarily suppresses a key component of the brain’s immune system can prevent radiation-associated cognitive decline.
In new studies conducted at UCSF, a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia.
A new spinal cord injury protocol, based on research by UCSF scientists, is a mixture of revised evaluations and new treatments to personalize care. It has spurred quicker recoveries for patients.
Thanks to a $6.7 million grant, the newly named UCSF-Stanford Pediatric Device Consortium can focus on the development of revolutionary, low-cost gadgets to diagnose and cure pediatric health conditions.
Researchers have identified a new strategy for potentially treating a subset of intractable cancers by decoupling the entire RAS / MAP Kinase signaling pathway from external growth signals.
Students who spent their summer doing laboratory and clinical research alongside BCHO doctors and CHORI scientists are presenting their research at a scientific symposium at CHORI on Friday, August 10.
A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease.
In an achievement that has significant implications for research, medicine, and industry, UCSF scientists have genetically reprogrammed human immune cells without using viruses to insert DNA
UCSF researchers have identified a key biological pathway in human cancer patients that appears to prime the immune system for a successful response to immunotherapy drugs – checkpoint inhibitors.